Market Access

Strategic Synergy: Integrating Regulatory Affairs & HTA

In the evolving landscapes of the EU and UK, the traditional “siloed” approach to drug development is no longer viable. With the implementation of the EU HTA Regulation (HTAR) and the UK’s increasingly collaborative MHRA/NICE Aligned Pathway, the bridge between Marketing Authorization (MA) and Market Access (HTA) has narrowed.

At Pharma Design, we specialize in the strategic integration of Regulatory and Health Technology Assessment (HTA) workstreams. We don’t just help you get a label; we help you get a price and a place in the market.

Why is Integration the New Standard?

New legislative frameworks in EU and UK now demand that clinical evidence satisfies two different masters simultaneously:

1. Regulators (EMA/MHRA): Focus on Benefit-Risk, Safety, and Quality.
2. HTA Bodies (NCPE, NICE, HAS, etc.): Focus on Relative Effectiveness and Cost-Utility.

By aligning these requirements during the development phase, we eliminate the “evidence gap” that often leads to delays in reimbursement or restrictive market access.

Our Integrated Service Pillars

1. Strategic Alignment of Early Milestones

We synchronize your regulatory milestones with HTA requirements to ensure every data point serves a dual purpose.

• Scientific Advice: Coordinating joint clinical advice to ensure endpoints satisfy both regulatory scrutiny and payer value assessment.
• Pediatric Investigation Plans (PIP): Ensuring pediatric data is robust enough for HTA evaluation.
• Expedited Pathways: Navigating PRIME (EU) and PIM/ILAP (UK) designations while front-loading HTA dossier preparation.

2. Joint Scientific Consultations (JSC)

Pharma Design has experience facilitating JSC meetings with the EMA and HTA bodies. We manage the complex preparation required for these meetings, helping you secure consensus on:

• Choice of comparator.
• Relevant patient-reported outcomes (PROs).
• Sub-group analysis requirements.

3. The Aligned Pathway (UK Focus)

Leveraging our deep expertise in the UK market, we assist clients in navigating the Innovative Licensing and Access Pathway (ILAP). We help bridge the gap between the MHRA’s safety review and NICE/SMC’s value assessment, ensuring a seamless transition from “Authorized” to “Available.”

4. Evidence Generation & Gap Analysis

We perform rigorous “stress tests” on your Phase II/III protocols to identify areas where HTA bodies might find the evidence insufficient, allowing for course correction long before the MAA filing.

The Pharma Design Advantage

• Legislative Fluency: We stay ahead of the latest EU HTAR requirements, ensuring your dossiers are compliant with the new mandatory joint clinical assessments.
• Reduced Time-to-Patient: By aligning HTA preparation with the MAA filing, we significantly reduce the “dead time” between regulatory approval and national reimbursement.
• Risk Mitigation: We identify conflicting requirements early, preventing the need for costly post-marketing trials.

“Regulatory approval is a milestone, but patient access is the goal. We design the path to achieve both.”

Ready to Align Your Strategy?

The complexity of the EU and UK markets requires a partner who understands the interplay between policy and science.